

Conclusion et Perspectives

Les formes variantes CGD X^+ et X^- sont de loin les plus intéressantes puisqu'elles permettent l'étude directe du lien entre une région précise de gp91^{phox} ou Nox2 et sa fonction (CGD X^+) ou son mécanisme d'expression (CGD X^-). La modélisation cellulaire de ces mutations humaines est nécessaire pour l'obtention d'un matériel biologique suffisamment abondant afin de permettre des études biochimiques approfondies. Le rôle joué par certains domaines spécifiques de gp91^{phox} dans le transfert électronique, l'activation, l'assemblage et la désactivation du complexe oxydase, mais également dans les processus de maturation de gp91^{phox}, pourront alors être étudiés au niveau moléculaire.

Le modèle utilisé au laboratoire est une lignée cellulaire pro-myélocytaire PLB-985 induite en neutrophile sous l'effet du diméthylformamide et dont le gène *CYBB* a été inactivé par recombinaison homologue (PLB-985 KO) mais possédant tous les autres composants de l'oxydase (p47^{phox}, p67^{phox}, p40^{phox} et Rac2). A l'heure actuelle une seule CGD X^+ a été reconstituée et étudiée par l'équipe de Mary Dinauer dans le modèle cellulaire PLB-985 (Yu et al. 1999).

L'approche expérimentale consiste à reproduire les mutations humaines dans le cDNA de gp91^{phox} par mutagenèse dirigée. Le clonage du cDNA sauvage et muté de gp91^{phox} est ensuite effectué dans un vecteur d'expression, pEF-PGK-neo, puis les différentes constructions sont introduites dans les cellules PLB-985 KO pour le gène *CYBB*, par électroporation. La sélection des clones positifs se fait par la méthode des dilutions limites en présence d'un antibiotique (la généticine). Après trois semaines de culture, les clones positifs sont repérés, les cellules sont cultivées toujours avec une pression de sélection. Lorsque le nombre de cellules est suffisant, la correction d'activité oxydase par transfection du cDNA de gp91^{phox} sauvage ainsi que l'impact des différentes mutations mimant la CGD X^+ ou la CGD X^- , sont évalués par mesure des dérivés toxiques de l'oxygène par chimiluminescence et par spectrophotométrie. L'expression de la protéine gp91^{phox} mutée ou sauvage est révélée par immuno-détection à l'aide d'anticorps monoclonaux spécifiquement dirigés contre cette protéine (Don du Dr. D. Roos, CLB, Amsterdam) et par cytométrie en flux (collaboration avec le Dr. J. Boutonnat, laboratoire de cytologie, CHU Grenoble et le Dr. J. Mathieu, Département de radiobiologie, CRSSA, Grenoble) grâce à un anticorps monoclonal 7D5 dirigé contre un épitope externe de gp91^{phox} (Don du Dr. Nakamura, Nagasaki, Japon). Cette dernière technique permet également de contrôler l'insertion membranaire correcte de gp91^{phox} muté. L'activité NADPH oxydase dans les cellules intactes est mesurée par le suivi de la production de H₂O₂ par chimiluminescence. L'activité oxydase reconstituée est mesurée par réduction du cytochrome *c* sensible à la SOD, en présence de membranes plasmiques (ou de cytochrome *b*₅₅₈ purifié), de facteurs cytosoliques (ou de protéines cytosoliques recombinantes purifiées), de NADPH, de GTPγS et d'acide arachidonique. L'assemblage du complexe oxydase *in vivo* est étudié par microscopie confocale en suivant la translocation du facteur cytosolique p47^{phox} à la membrane après stimulation des cellules PLB-985 transfectées par des particules de latex enrobées de PMA (Collaboration avec le Dr. D. Roos, CLB, Amsterdam, Hollande et le Dr. D. Grunwald, CIS, CEA, Grenoble).

⇒ La lignée PLB-985 KO pour le gène codant gp91^{phox} nous a déjà permis :

- De reconstituer une activité NADPH oxydase par transfection du cDNA de gp91^{phox} sauvage. Ceci constitue un essai de thérapie correctrice *ex-vivo*. L'activité NADPH oxydase générée est comparable à celle mesurée dans les cellules PLB-985 de type sauvage (100 % de restauration d'activité, expression de gp91^{phox} comparable à celle mesurée dans les PLB-985 sauvages).
- De reproduire par mutagénèse dirigée, les modèles de **CGD X⁺** que nous avons diagnostiqués au laboratoire.
- De reproduire un modèle de **CGD X⁻** (Ser193Phe) par mutagénèse dirigée.

Dans le cas de la **double mutation His303Asn/Pro304Arg** nous avons établi par transfection, des lignées cellulaires PLB-985 exprimant soit la mutation His303Asn, soit la seconde mutation Pro304Arg soit la double mutation. Nous avons pu vérifier que :

- la mutation His303Asn de gp91^{phox} est suffisante pour abolir totalement l'activité NADPH oxydase ainsi que l'assemblage du complexe oxydase *in vivo*.
- la mutation Pro304Arg inhibe en partie l'activité NADPH oxydase avec un effet partiel sur l'assemblage du complexe.
- Ainsi chacune de ces mutations ne constitue pas un polymorphisme mais seule la mutation His303Asn est responsable d'un défaut de translocation des facteurs cytosoliques et de leur assemblage au niveau du cytochrome *b*₅₅₈ pour la constitution d'une oxydase.
- L'étude du modèle 3D de la queue cytosolique C-terminale de Nox2 nous montre une localisation des His³⁰³ et Pro³⁰⁴ à la surface de la protéine, dans un environnement hydrophile compatible avec une éventuelle interaction avec les facteurs cytosoliques de l'oxydase (collaboration Dr. Eppink, Oss, Hollande). Ces acides aminés ne forment pas de liaisons hydrogène fortes avec les acides aminés alentour, et leur localisation n'est pas compatible pour interagir avec les sites de fixation du FAD ou du NADPH (distance minimale 6-7 Å).

La même approche a été utilisée pour l'étude d'un autre cas de **CGD X⁺** dû à une mutation faux-sens **Leu505Arg** sur Nox2. Nous avons pu montrer que le modèle cellulaire utilisé permet de reconstituer exactement le phénotype des neutrophiles du cas de **CGD X⁺**, comme dans le cas précédemment étudié. Malgré une activité oxydase nulle, la translocation des facteurs cytosoliques semble exister mais n'est vraisemblablement pas optimale. Étonnamment une activité NADPH oxydase et INT réductase pour le mutant ont été reconstituées *in vitro* à 50% par rapport au cytochrome *b*₅₅₈ WT, prouvant qu'un transfert électronique ainsi que l'assemblage de l'enzyme sont possibles dans certaines conditions.

Le K_m du NADPH et du NADH pour le cytochrome *b*₅₅₈ muté purifié, en présence de protéines recombinantes p67^{phox}, p47^{phox} et Rac, est augmenté de 3 fois alors que le turnover de l'enzyme est diminué de moitié. La mutation Leu505Arg gêne la fixation du NADPH sur son site mais ne semble pas être directement impliquée dans cette reconnaissance. Enfin il faut 3 fois plus de p67^{phox} en présence du cytochrome *b*₅₅₈ muté purifié que dans le cas du cytochrome *b*₅₅₈ WT pour obtenir une activité maximale de la NADPH oxydase, mais qui reste inférieure à celle du cytochrome *b*₅₅₈ WT. Le modèle 3D de la queue C-terminale cytosolique de Nox2 montre que la Leu⁵⁰⁵ possède une position stratégique pour l'accès au site de fixation du NADPH sans que cet acide aminé soit directement impliqué dans sa fixation (collaboration Dr. F. Fieschi, IBS, Grenoble). Cette mutation met l'accent sur

l'importance de la fonction de l'hélice α dans la liaison des facteurs cytosoliques, probablement p67^{phox}, et sur le rôle de cette liaison pour la fixation du NADPH à son site.

La même approche a été utilisée pour l'étude de la biosynthèse du cytochrome *b*₅₅₈ dans le cas de la CGD X⁻ (Ser193Phe). La mutation a été reproduite dans les lignées cellulaires PLB-985 et COS-7. Les cellules PLB-985, exprimant la mutation Ser193Phe, miment exactement le phénotype des neutrophiles issus du patient (Roesler et al. 1999), avec une expression diminuée du cytochrome *b*₅₅₈ associée à une activité oxydase abolie. Cette mutation inhibe la maturation de la protéine Nox2 dans les deux lignées cellulaires étudiées. D'autre part, dans les cellules PLB-985 transfectées, la mutation Ser193Phe inhibe l'expression de l'ARNm de Nox2 mutant.

Grâce à la mise en place de la méthodologie d'étude de l'impact des mutations humaines du gène *CYBB* sur le fonctionnement du complexe oxydase des phagocytes, nous avons pu explorer le rôle joué par **deux régions intra-cytosoliques de Nox2, la boucle D et une boucle formant une hélice α dans la partie C-terminale de Nox2** (Figure 7-Introduction).

L'impact des mutations générées dans la boucle D sur l'activité NADPH oxydase a été évalué par mesure des H₂O₂ totaux après activation par le PMA. Les cellules PLB-985 transfectées exprimant K195A-gp91^{phox}, K195E-gp91^{phox}, R198E-gp91^{phox}, R199E-gp91^{phox}, RR198199QQ-gp91^{phox} ont une activité NADPH oxydase totalement abolie. Ceci prouve l'importance des charges positives des Lys et Arg de la boucle D dans le maintien de l'activité NADPH oxydase, et notamment pour la Lys¹⁹⁵, l'abolition (A) ou le changement de charge (E) est délétère pour l'activité oxydase. Etonnamment la double mutation RR198199EE permet d'obtenir une activité oxydase de l'ordre de 60% par rapport aux cellules PLB-985 WT alors que les simples mutations (R198E ou R199E) abolissent complètement cette activité. Ceci prouve que la charge globale de la boucle D est également importante pour l'activité oxydase. Nous avons également voulu remplacer la boucle D de Nox2 par celle de Nox1, Nox3 ou Nox4. La Lys¹⁹⁵ est absente dans ces homologues de Nox2 alors que l'Arg¹⁹⁸ est conservée. Cependant nous remarquons que non seulement l'activité oxydase des protéines chimères gp91^{phox}-boucle D_{Nox1}, gp91^{phox}-boucle D_{Nox3}, gp91^{phox}-boucle D_{Nox4} n'est pas abolie mais elle est augmentée, et ceci est particulièrement significatif pour les cellules mutantes exprimant gp91^{phox}-boucle D_{Nox4}. Afin de contrôler au mieux l'impact des mutations de gp91^{phox} sur l'activité du complexe oxydase, un autre agent stimulant, le fMLP, a été utilisé pour activer les cellules PLB-985 WT et "transgéniques". Globalement nous obtenons les mêmes effets inhibiteurs de certaines mutations sur l'activité oxydase, lorsque les cellules sont activées par le PMA et le fMLP. Par contre certaines mutations et notamment celles de la boucle D, qui n'avaient aucun effet sur l'activité oxydase lorsque les cellules étaient stimulées par le PMA, provoquent une suractivation de cette enzyme lorsque les cellules PLB-985 "transgéniques" sont activées par le fMLP. En effet nous remarquons deux super-mutants gp91^{phox}-R199Q et gp91^{phox}-boucle D_{Nox4} qui présentent respectivement une activité oxydase multipliée par 8 et par 4 par rapport aux cellules WT. Nous pouvons peut être penser que le PMA et le fMLP empruntent des voies de signalisation différentes impliquant l'activation de kinases et/ou de phosphatases permettant un niveau de phosphorylation différent des facteurs cytosoliques p47^{phox} et/ou p67^{phox} modulant ainsi l'activité NADPH oxydase et son assemblage. Il se peut également que ces deux agents stimulants provoquent une localisation du complexe oxydase différente.

L'assemblage du complexe oxydase des lignées PLB-985 transfectées a ensuite été étudié par microscopie confocale, en suivant la translocation du facteur cytosolique p47^{phox} à la membrane des phagosomes après activation par des billes de latex enrobées de PMA. Nous avons tout d'abord validé la qualité de cette technique en effectuant un triple marquage, p47^{phox}-Alexa 488, gp91^{phox}-Alexa 568, l'ADN nucléaire-TO-PRO 3. Une acquisition séquentielle des images nous a permis de visualiser une co-localisation de p47^{phox} et de gp91^{phox} au niveau de la membrane des phagosomes dans les cellules PLB-985 WT. Les résultats obtenus avec la lignée Asp500Gly-Nox2 PLB-985 mimant le cas de CGD X⁺ décrit par l'équipe de D. Roos (Leusen et al. 1994) montrent une parfaite adéquation avec le comportement des neutrophiles du patient. En effet lors de l'activation de ces cellules par les billes de latex, gp91^{phox} se retrouve au niveau de la membrane du phagosome alors que p47^{phox} a une localisation strictement cytosolique, montrant un défaut d'assemblage du complexe oxydase. Pour les mutants de la boucle D nous avons remarqué une translocation correcte de p47^{phox} à la membrane, montrant que l'abolition de l'activité NADPH oxydase ne provenait pas d'un défaut d'assemblage du complexe. Les résultats de translocation *in vivo* de p47^{phox} ont été confirmés par la méthode plus classique d'activation de l'assemblage du complexe oxydase *in vitro*.

Dans un dernier volet, l'activité INT réductase, reflet du transfert électronique du NADPH vers le FAD au niveau de la partie cytosolique C-terminale de gp91^{phox}, a été évaluée. Clairement les mutants de la boucle D de gp91^{phox} ont une activité INT réductase équivalente à celle mesurée dans les cellules PLB-985 WT ou KO transfectées par l'ADNc de gp91^{phox} WT.

En ce qui concerne **les mutants de la queue cytosolique C-terminale de Nox2**, les mutations D484T, H490D, mais pas D484H et H490A, abolissent totalement l'activité NADPH oxydase. L'acide aminé Asp⁵⁰⁰ comme nous l'avons vu plus haut pour la Lys¹⁹⁵, semble essentiel au maintien de l'activité NADPH oxydase. En effet les charges négatives sont ici primordiales pour cette activité puisque les mutations D500A, D500R et D500G sont toutes délétères pour cette enzyme.

A la différence des mutants de la boucle D de Nox2, les mutants de la queue cytosolique C-terminale ne possédant pas d'activité oxydase (mutations D484T, D500A, D500R) montrent un défaut de translocation de p47^{phox}. Les résultats obtenus par l'équipe de M. Dinauer avec le double mutant RR9192EE de la boucle B de gp91^{phox} connu pour induire ce même défaut, ont été confirmés. L'activité INT réductase pour les mutants ne possédant pas d'activité oxydase, est totalement abolie signifiant qu'il n'y a pas de passage électronique du NADPH vers le FAD.

Finalement nous pouvons penser que les charges positives de la boucle D (Lys¹⁹⁵, Arg¹⁹⁸, Arg¹⁹⁹) ainsi que les charges négatives de la queue cytosolique C-terminale de gp91^{phox} formant une hélice α , sont indispensables au maintien de l'activité NADPH oxydase des phagocytes. Cependant seule l'hélice α semble impliquée dans les processus d'assemblage du complexe oxydase. La séquence C-terminale de gp91^{phox} centrée autour de l'Asp⁵⁰⁰ est essentielle pour l'assemblage du complexe oxydase et probablement pour une conformation adaptée de gp91^{phox}, permettant un transfert électronique correct du NADPH vers le FAD. Nous pouvons remarquer également que la boucle D est localisée dans une région très proche du 5ème passage transmembranaire de Nox2. Elle pourrait

ainsi permettre un contrôle du passage électronique du FAD vers l'oxygène *via* les hèmes. La mutation Ser193Phe à l'origine d'une CGD X⁻ en cours d'étude, met clairement en évidence que la boucle D, cruciale pour l'activité NADPH oxydase, est probablement impliquée dans le maintien d'une structure correcte du cytochrome *b*₅₅₈. Ces hypothèses restent à confirmer.

Perspectives

Pour les mutants dans la boucle-D

1. Etudier le mécanisme d'activation de l'oxydase dans les deux super-mutants (R199Q et gp91^{phox}-boucle D_{Nox4}).
2. Essayer de comprendre le défaut de la maturation de Nox2 dans le cas de CGD X⁻ (Ser193Phe).
 - 1) Abandonner le système COS-7.
 - 2) Transfecter Nox2 WT et mutée dans les cellules HEK 293 humaines pour vérifier le défaut de glycosylation observée dans les cellules PLB-985.
 - 3) Vérifier l'expression de ARNm de Nox2 WT et mutée dans le système PLB-985 et HEK 293 par Northern blot.
 - 4) Etudier la localisation sub-cellulaire des différentes formes de Nox2 WT et mutée et p22^{phox} dans ces deux lignées cellulaires.
 - 5) Analyser l'incorporation des hèmes dans Nox2 muté dans les deux types cellulaires par spectrophotométrie différentielle du cytochrome *b*₅₅₈.
 - 6) Etudier la synthèse de Nox2 muté à partir d'ARNm purifié en présence du système de synthèse protéique *in vitro* de réticulocytes de globules rouges de lapin.

Pour l'hélice α C-terminale de Nox2

3. Déterminer le rôle de l'hélice α C-terminale (acides aminés 484-504) sur l'activation du complexe oxydase. Un mutant délété de cette hélice pourra être étudié. En effet une grande partie des réductases de la famille FNR ne possède pas cette séquence en C-terminal et sont activables uniquement en présence de leur substrat sans assemblage préalable.

Les autres idées

4. Essayer de comprendre la relation entre le taux d'activité oxydase des cellules exprimant Nox2 muté, et la bactéricidie. Ceci permettra de déterminer le taux minimal d'ions superoxyde nécessaires pour tuer les bactéries.
5. Analyser des mutations localisées dans le site potentiel de fixation du NADPH, ou du FAD (Thr341Lys, Gly408Glu, Pro415His, Cys537Arg).

Conclusion and Perspectives

Mutagenesis and stable transfection approaches in the X-CGD PLB-985 cellular model were used to study the defective molecular mechanisms of three X⁺-CGD mutations, one X⁻-CGD substitution and the structure-function analysis of two important cytosolic domains of gp91^{phox} or Nox2. The X-CGD PLB-985 cells produced by *CYBB* gene targeting (Zhen et al. 1993) were a generous gift of Dr. M. Dinauer (University of Indianapolis, U.S.A).

Study of the defective molecular mechanism of three X⁺-CGD mutations in the transfected PLB-985 cells

CGD results from a defect in the NADPH oxidase system, composed of gp91^{phox}, p22^{phox}, p47^{phox}, p67^{phox} and Rac. Gp91^{phox}, harboring the binding sites for haems, FAD, and NADPH (Vignais 2002), is the catalytic center of the NADPH oxidase enzyme, and mutations in *CYBB* gene cause most of the CGD cases (Heyworth et al. 2003). X⁺-CGD is characterized by a normal level of a nonfunctional gp91^{phox} in phagocytes, providing an ideal system for studying functional domains in gp91^{phox} (Leusen et al. 1994; Cross et al. 1995a; Cross et al. 1995b; Yu et al. 1999; Stasia et al. 2002). Three X⁺-CGD mutations (the His303Asn/Pro304Arg and Leu505Arg mutations identified in our laboratory, and the Asp500Gly mutation found by Leusen *et al.*) were reproduced in the X-CGD PLB-985 cells harboring the same phenotype as the neutrophils from the X⁺ CGD patients (Leusen et al. 1994; Stasia et al. 2002; Stasia et al. 2005). Although these gp91^{phox} mutations have no effect on the expression and maturation of cytochrome *b*₅₅₈, no superoxide was generated in transfected PLB-985 cells.

His303Asn/Pro304Arg totally abolished the oxidase activity *in vivo* and *in vitro*. This inhibition is associated with a defective translocation of p47^{phox} and p67^{phox} to the plasma membranes of mutated cells. Separate analysis of His303Asn and Pro304Arg mutations showed that His303Asn is sufficient to abolish the NADPH oxidase activity, associated with a defective oxidase assembly, while Pro304Arg substitution has a less drastic effect. Meanwhile neither mutation could be considered as a polymorphism in the *CYBB* gene. The 3D-model study according to Taylor *et al.*, shows that these two residues are localized at the surface of gp91^{phox}, suggesting that these residues may participate to the oxidase assembly process directly or indirectly by maintaining a correct conformation of gp91^{phox} to bind cytosolic factors. The distance of His³⁰³ and Pro³⁰⁴ from the FAD and NADPH potential binding sites is not compatible with a possible interaction with them.

Asp500Gly mutation in gp91^{phox} totally inhibited the oxidase activity and assembly process in whole cells and in a cell-free system assay using membranes from Asp500Gly gp91^{phox} transfected PLB-985 cells. This X⁺-CGD mutation disturbed the electron transfer from NADPH to FAD, confirming the 3D model of Taylor and Segal (Taylor et al. 1993). Indeed Asp⁵⁰⁰ is located in an α -helical loop proposed to be a potential binding site for the cytosolic factors. In resting state this loop should covers the NADPH binding site and upon activation it should move aside, leaving free access for NADPH to the cleft containing its binding site.

Unlike both X⁺-CGD mutations described above, the NADPH oxidase inhibition

resulting from the Leu505Arg substitution is not related to a defect on oxidase cytosolic components translocation. According to the sequence alignment of Nox2 with members of FNR family, this Leu⁵⁰⁵ was proposed to be located in the adenine of NADPH binding site of Nox2 (Rotrosen et al. 1992; Vignais 2002). Interestingly in a CFS assay, 50% of the oxidase activity found in WT PLB-985 membranes could be restored using plasma membranes from Leu505Arg Nox2 PLB-985 cells. This was also demonstrated for the INT reductase activity suggesting that a partial electron transfer from NADPH to the molecular oxygen via FAD can occur. The K_m for NADPH and NADH of the purified cytochrome b_{558} from this mutant transfected cells is approximately 3-time higher than that of wild type, suggesting that this mutation slightly inhibits the affinity for NADPH and NADH. However, this inhibition is probably not compatible with a direct interaction of Leu⁵⁰⁵ with the adenine of NADPH. In addition the α helical loop insertion, only found in the members of Nox/Duox family and FRE1, covers the potential binding site of adenine of NADPH (⁵⁰⁴GLKQ⁵⁰⁷) shown in FNR members. An increasing amount of recombinant p67^{phox} in a CFS containing the Leu505Arg mutated cytochrome b_{558} could restore most of the oxidase activity measured in the wild type cytochrome b_{558} , indicating that the Leu505Arg mutation disturbs the affinity of p67^{phox} for the cytochrome b_{558} . The 3D model of the cytosolic C-terminus of gp91^{phox} demonstrates that Leu⁵⁰⁵ is located at the end of the α -helical loop at the surface of Nox2 just at the entry of the cleft containing the NADPH binding site. We suppose that this mutation can disturb efficient movement of α -helical loop resulting to a defective p67^{phox} binding to the α helical loop and a reduced access of NADPH to its binding site. This defect is partially restored *in vitro* with an artificial forcing on the interactions between the oxidase components.

Study of the cytochrome b_{558} biosynthesis defect in an X⁻-CGD case (Ser193Phe) reproduced in X-CGD PLB-985 and COS-7 cell lines

Finally the Ser193Phe Nox2 transfected PLB-985 cells mimic the phenotype of neutrophils from the X⁻-CGD patient (Roesler et al. 1999), characterized by low expression of mutant gp91^{phox} with a correlated p22^{phox} expression. This result provides further evidence that the X-CGD PLB-985 cell line is an ideal model for study X⁺-CGD and X⁻-CGD mutations (Yu et al. 1999; Bionda et al. 2004; Li et al. 2005). Ser¹⁹³ is located in the D loop which was demonstrated that it had no impact on the oxidase complex assembly (Li et al. 2005). This mutation disturbs the mRNA expression and/or stability in transfected PLB-985 cells, but not in the transfected COS-7 cells. The low expression of gp91^{phox} protein in these two cell lines was associated with a defective maturation of gp91^{phox}. In PLB-985 cellular model, this could be due to a defective interaction between the mutant gp65 precursor and p22^{phox}, or to a defect in glycosylation and/or haems incorporation within the mutant gp65. Reduced minus oxidized difference spectrum of a soluble extract from the S193F Nox2 transfected PLB-985 cells will be done to know if the haems are indeed incorporated in the gp65 precursor. In COS-7 cellular model, the low expression of gp91^{phox} is also due to a maturation defect but it seems not only to be a consequence of the Ser193Phe mutation but also seems to be a cell line dependent defect as recently described (Murillo et al. 2005).

Analysis of the second intra-cytoplasmic loop of gp91^{phox}

Gp91^{phox} contains four cytosolic regions, ¹MGNWVAVNEGL¹¹ sequence, the B loop

⁷⁰PVCRNLLSFLRGSSACCSTRIRRRQLDRNLTFHK¹⁰², the D loop ¹⁹¹TSSTKTIRRS²⁰⁰, and a C-terminal region containing binding sites for FAD and NADPH (Vignais 2002). Four cytoplasmic regions (residues 87-94, 451-458, 491-504, and 555-564) in gp91^{phox} have been suggested to interact with p47^{phox} and/or p67^{phox}. The X-CGD PLB-985 cell line has been used to investigate the D loop, which had never been studied, on the oxidase activity and assembly. The transfected PLB-985 cells expressed similar amounts of recombinant WT or mutant Nox2, which was crucial for comparing the impact of each mutation on the oxidase function in such cells. K195A/E mutant completely inhibited the oxidase activity in intact cells and CFS assay, indicating the Lys¹⁹⁵ is indispensable for the oxidase activity. The R198Q and RR198199EE mutations had little inhibitory effect on the oxidase activity, while R198E, R199E, RR198199QQ/AA mutations abolished the O₂⁻ generation *in vivo* and *in vitro*, suggesting that the total charge of Arg¹⁹⁸ and Arg¹⁹⁹ is important for maintaining the oxidase activity. However, the R199Q mutation had a “super” oxidase activity. Interestingly, the replacement of the D loop by the same region of the Nox2 homologues (Nox1, 3, 4) had a higher oxidase activity than that of Nox2, demonstrating that the D loop of Nox homologues is functional for the Nox2 activation process. We could conclude that the D loop has a similar role in human Nox family.

The translocation of the oxidase cytosolic components to the plasma membranes occurred normally in all the mutants of the D loop of Nox2, suggesting that this domain is not involved in the oxidase assembly process. The INT reductase activity of the mutants, which had no NADPH oxidase activity, could be totally reconstituted in a CFS assay, indicating that this region is not implicated in the electron transfer from NADPH to FAD.

In the two super-mutants (D loop_{Nox4}-Nox2 and R199Q) cells, the total H₂O₂ production was about 1.3-1.6 higher than in the WT PLB-985 cells after stimulation by PMA, and 5-8 times after fMLP activation. Higher H₂O₂ production was also observed in these super-mutants and D loop_{Nox1/3}-Nox2 after stimulation by ionomycin (Ca²⁺ ionophore) (data not shown). However, the over H₂O₂ production in intact cells was not reconstituted *in vitro*, suggesting that the cell-free system does not reproduce exactly what occurs *in vivo* (absence of phosphorylation).

Analysis of the α -helical loop (residues 484-500) of gp91^{phox}

As it was discussed before, the residues 484-504 form an α -helical loop in the C-terminal tail of gp91^{phox} (Taylor et al. 1993). This loop is only found in Nox/Duox family and FRE1, but not in the other members of FNR family. It covers the cleft in which NADPH binds, upon activation of the enzyme, it is believed to move aside to allow NADPH to access its binding site and fulfill its electron transfer to FAD. In this charged region, Asp⁴⁸⁴, His⁴⁹⁰, Asp⁴⁹⁶, and Asp⁵⁰⁰ are heavily conserved in the FNR family. D484T-Nox2 mutant completely inhibited NADPH oxidase activity *in vivo* and *in vitro*, while D484H had no significant inhibition on oxidase activity, suggesting that the charge in the residue 484 is absolutely necessary to maintain the oxidase activity. H490A-Nox2 transfected cells exhibited normal H₂O₂ production, while H490D lost most of the oxidase activity, indicating that the positive charge or neutral residue at 490 could also maintain the oxidase activity. D496H mutant had no effect on oxidase activity, suggesting that the charged residue is necessary for the H₂O₂ production.

However, D500A/R/G mutations destroy the oxidase activity in intact cells and in the CFS assay, demonstrating that the oxidase activity is absolutely dependent on the Asp⁵⁰⁰. Unfortunately the D500E mutation was not performed to know if the negative charge in the residue 500 was efficient to maintain the oxidase activity. Yet these data suggest that the charges in this α -helical loop are essential for the oxidase function.

D484T and D500A/R/G mutations led to a defective translocation of the oxidase cytosolic components *in vivo* and *in vitro* and an inhibition of INT reductase activity. This suggests that the dysfunction of oxidase activity is associated with a defect of the assembly process leading to a defective electron transfer from NADPH to FAD.

The main conclusion of the work is that X-CGD PLB-985 cellular model is useful and efficient for studying functional consequences of X⁺-CGD and X⁻-CGD or *de novo* mutations on oxidase activation process. His³⁰³ and Pro³⁰⁴ residues are essential to maintain a functional conformation of Nox2 for the oxidase activity and assembly. The D-loop of Nox2 is important for the oxidase activity, but not involved in the oxidase assembly and the electron transfer from NADPH to FAD. This loop is localized near the V transmembrane domain supporting haem- binding, it maybe involved in the electron transfer from FAD to molecular oxygen. The X⁻ CGD case with a Ser193Phe mutation in the D-loop, pointed out that this region maybe essential for the cytochrome *b*₅₅₈ structure (Roesler et al. 1999). This X⁻-CGD mutation (Ser193Phe) is associated with a defective maturation of Nox2 in the transfected PLB-985 cells and COS-7 cells. The α -helical loop (residues 484-504) is essential for NADPH activation and is also implicated in the oxidase assembly, which is associated with the electron transfer from NADPH to FAD. Finally Leu⁵⁰⁵ has a strategic position in Nox2, which is indispensable for an efficient interaction between Nox2 and p67^{phox}, leading to a correct NADPH binding.

Perspectives

For the D-loop mutants

1. Understand the molecular mechanism of the increased “respiratory burst” observed in the D loop_{Nox4}-Nox2 and R199Q super-mutants.
2. Determination of the sub-cellular localization of Nox2, its precursors p58 and gp65, of p22^{phox} in Ser193Phe-Nox2 transfected PLB-985 to find the limiting step for a correct cytochrome *b*₅₅₈ maturation. We will leave the COS-7 model for studying the gp91^{phox} maturation because of its special defect in the glycosylation system. Transfection of Ser193Phe-Nox2 cDNA in HEK293 human cells to verify the glycosylation defect observed in transfected PLB-985 cells. Study of the Nox2 synthesis from purified mRNA in an *in vitro* system using reticulocytes from rabbit red blood cells. Northern blot analysis of mRNA from the transfected PLB-985 and the HEK293 cells.

For the C-terminal α -helical loop

3. Clarify the role of the total α -helical loop (residues 484-504) on oxidase activation. This region will be totally deleted to produce a mutant which is supposed to have a constitutive oxidase activity devoid of cytosolic factors assembly. In addition FRE1 is the unique FNR reductase from *Saccharomyces cerevisiae* (Shatwell et al. 1996) proposed to be a flavocytochrome *b* which possesses a charged α -helical loop as Nox2. The idea is to transfect the WT cDNA FRE1 and a mutant cDNA devoid of the α -helical loop in X-CGD PLB-985 cell, to study the oxidase activity and the assembly of the complex under activation.

Other ideas...

4. We possess a series of Nox2 PLB-985 mutant cells which are able to produce different superoxide production level. The aim is to study the bactericidal power of these mutants to determine the minimal superoxide production level needed to kill bacteria. We would like to study in parallel, the membrane potential to verify the Dr. Segal's hypothesis that superoxide is not directly bactericidal, but leads to create a K⁺ influx inside the phagosome to liberate cationic proteases which are the real bactericidal agents (Reeves et al. 2002).
5. Investigation of other published X⁺-CGD mutations, which are located in the potential FAD- or NADPH-binding sites (Thr341Lys, Gly408Glu, Pro415His, Cys537Arg) to investigate their dysfunctional mechanism.

References

1. **Abo A**, Pick E, Hall A, Totty N, Teahan CG, Segal AW. (1991) Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. *Nature* 353, 668-670
2. **Abo A**, Boyhan A, West I, Thrasher AJ, Segal AW. (1992) Reconstitution of neutrophil NADPH oxidase activity in the cell-free system by four components: p67-phox, p47-phox, p21rac1, and cytochrome b-245. *J. Biol. Chem.* 267,16767-16770
3. **Ago T**, Kuribayashi F, Hiroaki H, Takeya R, Ito T, Kohda D, Sumimoto H. (2003) Phosphorylation of p47phox directs phox homology domain from SH3 domain toward phosphoinositides, leading to phagocyte NADPH oxidase activation. *Proc. Natl. Acad. Sci. U S A.* 100, 4474-4479
4. **Ahluwalia J**, Tinker A, Clapp LH, Duchon MR, Abramov AY, Pope S, Nobles M, Segal AW. (2004) The large-conductance Ca²⁺-activated K⁺ channel is essential for innate immunity. *Nature* 427, 853-858
5. **Ambasta RK**, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. (2004) Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. *J. Biol. Chem.* 279, 45935-45941
6. **Ariga T**, Sakiyama Y, Tomizawa K, Imajoh-Ohmi S, Kanegasaki S, Matsumoto S. (1993) A newly recognized point mutation in the cytochrome b558 heavy chain gene replacing alanine57 by glutamic acid, in a patient with cytochrome b positive X-linked chronic granulomatous disease. *Eur. J. Pediatr.* 152, 469-472
7. **Ariga T**, Sakiyama Y, Matsumoto S. (1994) Two novel point mutations in the cytochrome b 558 heavy chain gene, detected in two Japanese patients with X-linked chronic granulomatous disease. *Hum. Genet.* 94, 441
8. **Ariga T**, Furuta H, Cho K, Sakiyama Y. (1998) Genetic analysis of 13 families with X-linked chronic granulomatous disease reveals a low proportion of sporadic patients and a high proportion of sporadic carriers. *Pediatr. Res.* 44, 85-92
9. **Azuma H**, Oomi H, Sasaki K, Kawabata I, Sakaino T, Koyano S, Suzutani T, Nuno H, Okuno A. (1995) A new mutation in exon 12 of the gp91-phox gene leading to cytochrome b-positive X-linked chronic granulomatous disease. *Blood* 85, 3274-3277
10. **Babior BM**, Kipnes RS. (1977) Superoxide-forming enzyme from human neutrophils: evidence for a flavin requirement. *Blood* 50, 517-524
11. **Babior BM**. (1984) The respiratory burst of phagocytes. *J. Clin. Invest.* 73, 599-601
12. **Baldrige CW**, Gerard RW. (1933) The extra respiration of phagocytosis. *Am. J. Physiol.* 103, p.235-236
13. **Banfi B**, Schrenzel J, Nusse O, Lew DP, Ligeti E, Krause KH, Demaurex N. (1999) A novel H(+) conductance in eosinophils: unique characteristics and absence in chronic granulomatous disease. *J. Exp. Med.* 190, 183-194
14. **Banfi B**, Maturana A, Jaconi S, Arnaudeau S, Laforge T, Sinha B, Ligeti E, Demaurex N, Krause KH. (2000) A mammalian H⁺ channel generated through alternative splicing of the NADPH oxidase homolog NOH-1. *Science* 287, 138-142
15. **Banfi B**, Molnar G, Maturana A, Steger K, Hegedus B, Demaurex N, Krause KH. (2001) A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. *J. Biol. Chem.* 276, 37594-37601
16. **Banfi B**, Clark RA, Steger K, Krause KH. (2003) Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. *J. Biol. Chem.* 278, 3510-3513
17. **Banfi B**, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH. (2004) NOX3, a superoxide-generating NADPH oxidase of the inner ear. *J. Biol. Chem.* 279, 46065-46072

18. **Bellavite P**, Cross AR, Serra MC, Davoli A, Jones OT, Rossi F. (1983) The cytochrome b and flavin content and properties of the O₂-forming NADPH oxidase solubilized from activated neutrophils. *Biochim. Biophys. Acta.* 746, 40-47
19. **Berthier S**, Paquet MH, Lerouge S, Roux F, Vergnaud S, Coleman AW, Morel F. (2003) Changing the conformation state of cytochrome b558 initiates NADPH oxidase activation: MRP8/MRP14 regulation. *J. Biol. Chem.* 278, 25499-25508
20. **Biberstine-Kinkade KJ**, Yu L, Dinauer MC. (1999) Mutagenesis of an arginine- and lysine-rich domain in the gp91(phox) subunit of the phagocyte NADPH-oxidase flavocytochrome b558. *J. Biol. Chem.* 274, 10451-10457
21. **Biberstine-Kinkade KJ**, DeLeo FR, Epstein RI, LeRoy BA, Nauseef WM, Dinauer MC. (2001) Heme-ligating histidines in flavocytochrome b(558): identification of specific histidines in gp91(phox). *J. Biol. Chem.* 276, 31105-31112
22. **Biberstine-Kinkade KJ**, Yu L, Stull N, LeRoy B, Bennett S, Cross A, Dinauer MC. (2002) Mutagenesis of p22(phox) histidine 94. A histidine in this position is not required for flavocytochrome b558 function. *J. Biol. Chem.* 277, 30368-30374
23. **Bionda C**, Li XJ, van Bruggen R, Eppink M, Roos D, Morel F, Stasia MJ. (2004) Functional analysis of two-amino acid substitutions in gp91 phox in a patient with X-linked flavocytochrome b558-positive chronic granulomatous disease by means of transgenic PLB-985 cells. *Hum. Genet.* 115, 418-427
24. **Bjorgvinsdottir H**, Zhen L, Dinauer MC. (1996) Cloning of murine gp91phox cDNA and functional expression in a human X-linked chronic granulomatous disease cell line. *Blood* 87, 2005-2010
25. **Bokoch GM**, Quilliam LA, Bohl BP, Jesaitis AJ, Quinn MT. (1991) Inhibition of Rap1A binding to cytochrome b558 of NADPH oxidase by phosphorylation of Rap1A. *Science* 254, 1794-1796
26. **Bolscher BG**, de Boer M, de Klein A, Weening RS, Roos D. (1991) Point mutations in the beta-subunit of cytochrome b558 leading to X-linked chronic granulomatous disease. *Blood* 77, 2482-2487
27. **Borregaard N**, Heiple JM, Simons ER, Clark RA. (1983) Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation. *J. Cell Biol.* 97, 52-61
28. **Bromberg Y**, Pick E. (1985) Activation of NADPH-dependent superoxide production in a cell-free system by sodium dodecyl sulfate. *J. Biol. Chem.* 260, 13539-13545
29. **Bu-Ghanim HN**, Segal AW, Keep NH, Casimir CM. (1995) Molecular analysis in three cases of X912 variant chronic granulomatous disease. *Blood* 86, 3575-3582
30. **Burritt JB**, DeLeo FR, McDonald CL, Prigge JR, Dinauer MC, Nakamura M, Nauseef WM, Jesaitis AJ. (2001) Phage display epitope mapping of human neutrophil flavocytochrome b558. Identification of two juxtaposed extracellular domains. *J. Biol. Chem.* 276, 2053-2061
31. **Calvino MC**, Maldonado MS, Otheo E, Munoz A, Couselo JM, Burgaleta C. (1996) Bone marrow transplantation in chronic granulomatous disease. *Eur. J. Pediatr.* 155, 877-879
32. **Carstanjen D**, Yamauchi A, Koornneef A, Zang H, Filippi MD, Harris C, Towe J, Atkinson S, Zheng Y, Dinauer MC, Williams DA. (2005) Rac2 regulates neutrophil chemotaxis, superoxide production, and myeloid colony formation through multiple distinct effector pathways. *J. Immunol.* 174, 4613-4620
33. **Casimir CM**, Bu-Ghanim HN, Rodaway AR, Bentley DL, Rowe P, Segal AW. (1991) Autosomal recessive chronic granulomatous disease caused by deletion at a dinucleotide repeat. *Proc. Natl. Acad. Sci. U S A.* 88, 2753-2757
34. **Cheng G**, Cao Z, Xu X, van Meir EG, Lambeth JD. (2001) Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. *Gene* 269, 131-140

35. **Cheng G**, Lambeth JD. (2004) NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox homology (PX) domain. *J. Biol. Chem.* 279, 4737-4742
36. **Cross AR**, Parkinson JF, Jones OT. (1984) The superoxide-generating oxidase of leucocytes. NADPH-dependent reduction of flavin and cytochrome b in solubilized preparations. *Biochem. J.* 223, 337-344
37. **Cross AR**. (1987) The inhibitory effects of some iodonium compounds on the superoxide generating system of neutrophils and their failure to inhibit diaphorase activity. *Biochem. Pharmacol.* 36, 489-493
38. **Cross AR**, Yarchover JL, Curnutte JT. (1994) The superoxide-generating system of human neutrophils possesses a novel diaphorase activity. Evidence for distinct regulation of electron flow within NADPH oxidase by p67-phox and p47-phox. *J. Biol. Chem.* 269, 21448-21454
39. **Cross AR**, Heyworth PG, Rae J, Curnutte JT. (1995a) A variant X-linked chronic granulomatous disease patient (X91+) with partially functional cytochrome b. *J. Biol. Chem.* 270, 8194-8200
40. **Cross AR**, Rae J, Curnutte JT. (1995b) Cytochrome b-245 of the neutrophil superoxide-generating system contains two nonidentical hemes. Potentiometric studies of a mutant form of gp91phox. *J. Biol. Chem.* 270, 17075-17077
41. **Cross AR**, Noack D, Rae J, Curnutte JT, Heyworth PG. (2000) Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (first update). *Blood Cells Mol. Dis.* 26, 561-565
42. **Cross AR**, Segal AW. (2004) The NADPH oxidase of professional phagocytes--prototype of the NOX electron transport chain systems. *Biochim. Biophys. Acta.* 1657, 1-22
43. **Curnutte JT**. (1995) Disorders of phagocyte function. In *Hematology: Basic Principles and Practice* (Hoffman, R., Benz, E. J., Jr., Shattil, S. J., Furie, B., Cohen, H. J., and Silberstein, L. E., Eds.), p. 792. Churchill Livingstone, New York.
44. **Dahan I**, Issaeva I, Gorzalczany Y, Sigal N, Hirshberg M, Pick E. (2002) Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by "peptide walking". *J. Biol. Chem.* 277, 8421-8432
45. **Dang PM**, Babior BM, Smith RM. (1999) NADPH dehydrogenase activity of p67PHOX, a cytosolic subunit of the leukocyte NADPH oxidase. *Biochemistry* 38, 5746-5753
46. **Dang PM**, Cross AR, Babior BM. (2001) Assembly of the neutrophil respiratory burst oxidase: a direct interaction between p67PHOX and cytochrome b558. *Proc. Natl. Acad. Sci. U S A.* 98, 3001-3005
47. **Dang PM**, Cross AR, Quinn MT, Babior BM. (2002) Assembly of the neutrophil respiratory burst oxidase: a direct interaction between p67PHOX and cytochrome b558 II. *Proc. Natl. Acad. Sci. U S A.* 99, 4262-4265
48. **De Boer M**, de Klein A, Hossle JP, Seger R, Corbeel L, Weening RS, Roos D. (1992) Cytochrome b558-negative, autosomal recessive chronic granulomatous disease: two new mutations in the cytochrome b558 light chain of the NADPH oxidase (p22-phox). *Am. J. Hum. Genet.* 51, 1127-1135
49. **De Deken X**, Wang D, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE, Miot F. (2000) Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. *J. Biol. Chem.* 275, 23227-23233
50. **De Mendez I**, Leto TL. (1995) Functional reconstitution of the phagocyte NADPH oxidase by transfection of its multiple components in a heterologous system. *Blood* 85, 1104-1110
51. **De Mendez I**, Adams AG, Sokolic RA, Malech HL, Leto TL. (1996) Multiple SH3 domain interactions regulate NADPH oxidase assembly in whole cells. *EMBO J.* 15, 1211-1220

52. **DeCoursey TE**, Cherny VV, Zhou W, Thomas LL. (2000) Simultaneous activation of NADPH oxidase-related proton and electron currents in human neutrophils. *Proc. Natl. Acad. Sci. U S A.* 97, 6885-6889
53. **DeCoursey TE**, Cherny VV, Morgan D, Katz BZ, Dinauer MC. (2001) The gp91phox component of NADPH oxidase is not the voltage-gated proton channel in phagocytes, but it helps. *J. Biol. Chem.* 276, 36063-36066
54. **DeLeo FR**, Yu L, Burritt JB, Loetterle LR, Bond CW, Jesaitis AJ, Quinn MT. (1995a) Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence peptide phage display libraries. *Proc. Natl. Acad. Sci. U S A.* 92, 7110-7114
55. **DeLeo FR**, Nauseef WM, Jesaitis AJ, Burritt JB, Clark RA, Quinn MT. (1995b) A domain of p47phox that interacts with human neutrophil flavocytochrome b558. *J. Biol. Chem.* 270, 26246-26251
56. **DeLeo FR**, Ulman KV, Davis AR, Jutila KL, Quinn MT. (1996) Assembly of the human neutrophil NADPH oxidase involves binding of p67phox and flavocytochrome b to a common functional domain in p47phox. *J. Biol. Chem.* 271, 17013-17020
57. **DeLeo FR**, Burritt JB, Yu L, Jesaitis AJ, Dinauer MC, Nauseef WM. (2000) Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly. *J. Biol. Chem.* 275, 13986-13993
58. **Diekmann D**, Abo A, Johnston C, Segal AW, Hall A. (1994) Interaction of Rac with p67phox and regulation of phagocytic NADPH oxidase activity. *Science* 265, 531-533
59. **Dinauer MC**, Curnutte JT, Rosen H, Orkin SH. (1989) A missense mutation in the neutrophil cytochrome b heavy chain in cytochrome-positive X-linked chronic granulomatous disease. *J. Clin. Invest.* 84, 2012-2016
60. **Dinauer MC**, Pierce EA, Bruns GA, Curnutte JT, Orkin SH. (1990) Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. *J. Clin. Invest.* 86, 1729-1737
61. **Dinauer MC**, Pierce EA, Erickson RW, Muhlebach TJ, Messner H, Orkin SH, Seger RA, Curnutte JT. (1991) Point mutation in the cytoplasmic domain of the neutrophil p22-phox cytochrome b subunit is associated with a nonfunctional NADPH oxidase and chronic granulomatous disease. *Proc. Natl. Acad. Sci. U S A.* 88, 11231-11235
62. **Doussiere J**, Laporte F, Vignais PV. (1986) Photolabeling of a O₂⁻ generating protein in bovine polymorphonuclear neutrophils by an arylazido NADP⁺ analog. *Biochem. Biophys. Res. Commun.* 139, 85-93
63. **Doussiere J**, Brandolin G, Derrien V, Vignais PV. (1993) Critical assessment of the presence of an NADPH binding site on neutrophil cytochrome b558 by photoaffinity and immunochemical labeling. *Biochemistry* 32, 8880-8887
64. **Dusi S**, Rossi F. (1993) Activation of NADPH oxidase of human neutrophils involves the phosphorylation and the translocation of cytosolic p67phox. *Biochem. J.* 296, 367-371
65. **Dusi S**, Nadalini KA, Donini M, Zentilin L, Wientjes FB, Roos D, Giacca M, Rossi F. (1998) Nicotinamide-adenine dinucleotide phosphate oxidase assembly and activation in EBV-transformed B lymphoblastoid cell lines of normal and chronic granulomatous disease patients. *J. Immunol.* 161, 4968-4974
66. **El Benna J**, Faust LP, Babior BM. (1994) The phosphorylation of the respiratory burst oxidase component p47phox during neutrophil activation. Phosphorylation of sites recognized by protein kinase C and by proline-directed kinases. *J. Biol. Chem.* 269, 23431-23436

67. **El Benna J**, Faust RP, Johnson JL and Babior BM. (1996) Phosphorylation of the respiratory burst oxidase subunit p47phox as determined by two-dimensional phosphopeptide mapping: phosphorylation by protein kinase C, protein kinase A, and a mitogen-activated protein kinase. *J. Biol. Chem.* 271, 6374–6378
68. **Faust LR**, El Benna J, Babior BM and Chanock SJ. (1995) The phosphorylation targets of p47phox, a subunit of the respiratory burst oxidase: functions of the individual target serines as evaluated by site-directed mutagenesis. *J. Clin. Invest.* 96, 1499–1505
69. **Fontayne A**, Dang PM, Gougerot-Pocidallo MA, El-Benna J. (2002) Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. *Biochemistry* 41, 7743-7750
70. **Forbes LV**, Truong O, Wientjes FB, Moss SJ, Segal AW. (1999) The major phosphorylation site of the NADPH oxidase component p67phox is Thr233. *Biochem. J.* 338, 99-105
71. **Foubert TR**, Bleazard JB, Burritt JB, Gripenrog JM, Baniulis D, Taylor RM, Jesaitis AJ. (2001) Identification of a spectrally stable proteolytic fragment of human neutrophil flavocytochrome b composed of the NH2-terminal regions of gp91(phox) and p22(phox). *J. Biol. Chem.* 276, 38852-38861
72. **Freeman JL**, Lambeth JD. (1996) NADPH oxidase activity is independent of p47phox in vitro. *J. Biol. Chem.* 271, 22578-22582
73. **Gabig TG**, Crean CD, Mantel PL, Rosli R. (1995) Function of wild-type or mutant Rac2 and Rap1a GTPases in differentiated HL60 cell NADPH oxidase activation. *Blood* 85, 804–811
74. **Gauss KA**, Mascolo PL, Siemsen DW, Nelson LK, Bunger PL, Pagano PJ, Quinn MT. (2002) Cloning and sequencing of rabbit leukocyte NADPH oxidase genes reveals a unique p67(phox) homolog. *J. Leukoc. Biol.* 71, 319-328
75. **Geiszt M**, Kopp JB, Varnai P, Leto TL. (2000) Identification of renox, an NAD(P)H oxidase in kidney. *Proc. Natl. Acad. Sci. U S A.* 97, 8010-8014
76. **Geiszt M**, Lekstrom K, Witt J, Leto TL. (2003a) Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. *J. Biol. Chem.* 278, 20006-20012
77. **Geiszt M**, Lekstrom K, Brenner S, Hewitt SM, Dana R, Malech HL, Leto TL. (2003b) NAD(P)H oxidase 1, a product of differentiated colon epithelial cells, can partially replace glycoprotein 91phox in the regulated production of superoxide by phagocytes. *J. Immunol.* 171, 299-306
78. **Grizot S**, Faure J, Fieschi F, Vignais PV, Dagher MC, Pebay-Peyroula E. (2001a) Crystal structure of the Rac1-RhoGDI complex involved in NADPH oxidase activation. *Biochemistry* 40, 10007–10013
79. **Grizot S**, Grandvaux N, Fieschi F, Faure J, Massenet C, Andrieu JP, Fuchs A, Vignais PV, Timmins PA, Dagher MC, Pebay-Peyroula E. (2001b) Small angle neutron scattering and gel filtration analyses of neutrophil NADPH oxidase cytosolic factors highlight the role of the C-terminal end of p47phox in the association with p40phox. *Biochemistry* 40, 3127–3133
80. **Groemping Y**, Rittinger K. (2005) Activation and assembly of the NADPH oxidase: a structural perspective. *Biochem. J.* 386, 401-416
81. **Gu Y**, Jia B, Yang FC, D'Souza M, Harris CE, Derrow CW, Zheng Y, Williams DA. (2001) Biochemical and biological characterization of a human Rac2 GTPase mutant associated with phagocytic immunodeficiency. *J. Biol. Chem.* 276, 15929-15938
82. **Han CH**, Freeman JL, Lee T, Motalebi SA, Lambeth JD. (1998) Regulation of the neutrophil respiratory burst oxidase. Identification of an activation domain in p67(phox). *J. Biol. Chem.* 273, 16663-16668
83. **Hara T**, Kume A, Hanazono Y, Mizukami H, Okada T, Tsurumi H, Moriwaki H, Ueda Y, Hasegawa M, Ozawa K. (2004) Expansion of genetically corrected neutrophils in chronic granulomatous disease mice by cotransferring a therapeutic gene and a selective amplifier gene. *Gene Ther.* 11, 1370-1377

84. **Harper AM**, Chaplin MF, Segal AW. (1985) Cytochrome b-245 from human neutrophils is a glycoprotein. *Biochem. J.* 227, 783-788
85. **Hashida S**, Yuzawa S, Suzuki NN, Fujioka Y, Takikawa T, Sumimoto H, Inagaki F, Fujii H. (2004) Binding of FAD to cytochrome b558 is facilitated during activation of the phagocyte NADPH oxidase, leading to superoxide production. *J. Biol. Chem.* 279, 26378-26386
86. **Heidari Y**, Shah AM, Gove C. (2004) NOX-2S is a new member of the NOX family of NADPH oxidases. *Gene* 335, 133-140
87. **Henderson LM**, Chappell JB, Jones OT. (1987) The superoxide-generating NADPH oxidase of human neutrophils is electrogenic and associated with an H⁺ channel. : *Biochem. J.* 246, 325-329
88. **Henderson LM**, Banting G, Chappell JB. (1995) The arachidonate-activable, NADPH oxidase-associated H⁺ channel. Evidence that gp91-phox functions as an essential part of the channel. *J. Biol. Chem.* 270, 5909-5916
89. **Henderson LM**, Chappell JB. (1996) NADPH oxidase of neutrophils. *Biochim. Biophys. Acta.* 1273, 87-107
90. **Henderson LM**, Thomas S, Banting G, Chappell JB. (1997) The arachidonate-activatable, NADPH oxidase-associated H⁺ channel is contained within the multi-membrane-spanning N-terminal region of gp91-phox. *Biochem. J.* 325, 701-705
91. **Henderson LM**. (1998) Role of histidines identified by mutagenesis in the NADPH oxidase-associated H⁺ channel. *J. Biol. Chem.* 273, 33216-33223
92. **Henderson LM**, Meech RW. (1999) Evidence that the product of the human X-linked CGD gene, gp91-phox, is a voltage-gated H(+) pathway. *J. Gen. Physiol.* 114, 771-786
93. **Heyneman RA**, Vercauteren RE. (1984) Activation of a NADPH oxidase from horse polymorphonuclear leukocytes in a cell-free system. *J. Leukoc. Biol.* 36, 751-759
94. **Heyworth PG**, Curnutte JT, Nauseef WM, Volpp BD, Pearson DW, Rosen H, Clark RA. (1991) Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. *J. Clin. Invest.* 87, 352-356
95. **Heyworth PG**, Bohl BP, Bokoch GM, Curnutte JT. (1994) Rac translocates independently of the neutrophil NADPH oxidase components p47phox and p67phox. Evidence for its interaction with flavocytochrome b558. *J. Biol. Chem.* 269, 30749-30752
96. **Heyworth PG**, Curnutte JT, Rae J, Noack D, Roos D, van Koppen E, Cross AR. (2001) Hematologically important mutations: X-linked chronic granulomatous disease (second update). *Blood Cells Mol. Dis.* 27, 16-26
97. **Heyworth PG**, Cross AR, Curnutte JT. (2003) Chronic granulomatous disease. *Curr. Opin. Immunol.* 15, 578-584
98. **Hiroaki H**, Ago T, Ito T, Sumimoto H, Kohda D. (2001) Solution structure of the PX domain, a target of the SH3 domain. *Nat. Struct. Biol.* 8, 526-530
99. **Ho CM**, Vowels MR, Lockwood L, Ziegler JB. (1996) Successful bone marrow transplantation in a child with X-linked chronic granulomatous disease. *Bone Marrow Transplant.* 18, 213-215
100. **Holmes AM**, Stretton TB. (1967) Wegener's granulomatosis with abnormal arterial pressure response to the Valsalva manoeuvre. *Postgrad. Med. J.* 43, 425-427
101. **Hossle JP**, Berthet F, Erny C, Seger RA. (1993) Molecular genetic analysis of phagocyte oxidase cytochrome b558 mutations leading to chronic granulomatous disease. *Immunodeficiency* 4, 303-306
102. **Huang J**, Hitt ND, Kleinberg ME. (1995) Stoichiometry of p22-phox and gp91-phox in phagocyte cytochrome b558. *Biochemistry* 34, 16753-16757

- 103. Inanami O**, Johnson JL, McAdara JK, Benna JE, Faust LR, Newburger PE, Babior BM. (1998) Activation of the leukocyte NADPH oxidase by phorbol ester requires the phosphorylation of p47PHOX on serine 303 or 304. *J. Biol. Chem.* 273, 9539-9543
- 104. Ito T**, Matsui Y, Ago T, Ota K, Sumimoto H. (2001) Novel modular domain PB1 recognizes PC motif to mediate functional protein-protein interactions. *EMBO J.* 20, 3938-3946
- 105. Jesaitis AJ**. (1995) Structure of human phagocyte cytochrome b and its relationship to microbicidal superoxide production. *J. Immunol.* 155, 3286-3288
- 106. Jirapongsananuruk O**, Niemela JE, Malech HL, Fleisher TA. (2002) CYBB mutation analysis in X-linked chronic granulomatous disease. *Clin. Immunol.* 104, 73-76
- 107. Johnson JL**, Park JW, El Benna J, Faust LP, Inanami O and Babior BM. (1998) Activation of p47(PHOX), a cytosolic subunit of the leukocyte NADPH oxidase: phosphorylation of ser-359 or ser-370 precedes phosphorylation at other sites and is required for activity. *J. Biol. Chem.* 273, 35147-35152
- 108. Johnston RB**, Newman SL. (1977) Chronic granulomatous disease. *Pediatr. Clin. North Am.* 24, 365-376
- 109. Kakinuma K**, Kaneda M, Chiba T, Ohnishi T. (1986) Electron spin resonance studies on a flavoprotein in neutrophil plasma membranes. Redox potentials of the flavin and its participation in NADPH oxidase. *J. Biol. Chem.* 261, 9426-9432
- 110. Kakinuma K**, Fukuhara Y, Kaneda M. (1987) The respiratory burst oxidase of neutrophils. Separation of an FAD enzyme and its characterization. *J. Biol. Chem.* 262, 12316-12322
- 111. Kanai F**, Liu H, Field SJ, Akbary H, Matsuo T, Brown GE, Cantley LC, Yaffe MB. (2001) The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. *Nat. Cell Biol.* 3, 675-678
- 112. Karathanassis D**, Stahelin RV, Bravo J, Perisic O, Pacold CM, Cho W, Williams RL. (2002) Binding of the PX domain of p47(phox) to phosphatidylinositol 3,4-bisphosphate and phosphatidic acid is masked by an intramolecular interaction. *EMBO J.* 21, 5057-5068
- 113. Karplus PA**, Daniels MJ, Herriott JR. (1991) Atomic structure of ferredoxin-NADP+ reductase: prototype for a structurally novel flavoenzyme family. *Science* 251, 60-66
- 114. Kleinberg ME**, Malech HL, Rotrosen D. (1990) The phagocyte 47-kilodalton cytosolic oxidase protein is an early reactant in activation of the respiratory burst. *J. Biol. Chem.* 265, 15577-15583
- 115. Kleinberg ME**, Mital D, Rotrosen D, Malech HL. (1992) Characterization of a phagocyte cytochrome b558 91-kilodalton subunit functional domain: identification of peptide sequence and amino acids essential for activity. *Biochemistry* 31, 2686-2690
- 116. Knaus UG**, Heyworth PG, Evans T, Curnutte JT, Bokoch GM. (1991) Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. *Science* 254, 1512-1515
- 117. Koga H**, Terasawa H, Nunoi H, Takeshige K, Inagaki F, Sumimoto H. (1999) Tetratricopeptide repeat (TPR) motifs of p67(phox) participate in interaction with the small GTPase Rac and activation of the phagocyte NADPH oxidase. *J. Biol. Chem.* 274, 25051-25060
- 118. Koshkin, V**, Lotan, O, Pick E. (1996) The cytosolic component p47(phox) is not a sine qua non participant in the activation of NADPH oxidase but is required for optimal superoxide production. *J. Biol. Chem.* 271, 30326-30329
- 119. Kunkel LM**, Monaco AP, Middlesworth W, Ochs HD, Latt SA. (1985) Specific cloning of DNA fragments absent from the DNA of a male patient with an X chromosome deletion. *Proc. Natl. Acad. Sci. U S A.* 82, 4778-4782
- 120. Kuribayashi F**, Kumatori A, Suzuki S, Nakamura M, Matsumoto T, Tsuji Y. (1995) Human peripheral eosinophils have a specific mechanism to express gp91-phox, the large subunit of cytochrome b558. *Biochem. Biophys. Res. Commun.* 209, 146-152

- 121. Kuribayashi F**, de Boer M, Leusen JH, Verhoeven AJ, Roos D. (1996) A novel polymorphism in the coding region of CYBB, the human gp91-phox gene. *Hum. Genet.* 97, 611-613
- 122. Kuribayashi F**, Nunoi H, Wakamatsu K, Tsunawaki S, Sato K, Ito T, Sumimoto H. (2002) The adaptor protein p40(phox) as a positive regulator of the superoxide-producing phagocyte oxidase. *EMBO J.* 21, 6312-632
- 123. Labadia ME**, Bokoch GM, and Huang CK. (1993) The Rap1A protein enhances protein kinase C activity in vitro. *Biochem. Biophys. Res. Commun.* 195, 1321-1328
- 124. Labro MT.** (2000) Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or "Immuno-Fairy Tales"? *Clinical Microbiology Reviews* 13, 615-650
- 125. Lambeth JD.** (2002) Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) oxidases. *Curr. Opin. Hematol.* 9, 11-17
- 126. Lambeth JD.** (2004) NOX enzymes and the biology of reactive oxygen. *Nat. Rev. Immunol.* 4, 181-189
- 127. Lapouge K**, Smith SJ, Walker PA, Gamblin SJ, Smerdon SJ, Rittinger K. (2000) Structure of the TPR domain of p67phox in complex with Rac.GTP. *Mol. Cell* 6, 899-907
- 128. Lapouge K**, Smith SJ, Groemping Y, Rittinger, K. (2002) Architecture of the p40-p47-p67phox complex in the resting state of the NADPH oxidase. A central role for p67phox. *J. Biol. Chem.* 277, 10121 – 10128
- 129. Leto TL**, Lomax KJ, Volpp BD, Nunoi H, Sechler JM, Nauseef WM, Clark RA, Gallin JI, Malech HL. (1990) Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. *Science* 248, 727-730
- 130. Leto TL**, Adams AG, de Mendez I. (1994) Assembly of the phagocyte NADPH oxidase: binding of Src homology 3 domains to proline-rich targets. *Proc. Natl. Acad. Sci. U S A.* 91, 10650-10654
- 131. Leusen JH**, de Boer M, Bolscher BG, Hilarius PM, Weening RS, Ochs HD, Roos D, Verhoeven AJ. (1994a) A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox. *J. Clin. Invest.* 93, 2120-2126
- 132. Leusen JH**, Bolscher BG, Hilarius PM, Weening RS, Kaulfersch W, Seger RA, Roos D, Verhoeven AJ. (1994b) 156Pro-->Gln substitution in the light chain of cytochrome b558 of the human NADPH oxidase (p22-phox) leads to defective translocation of the cytosolic proteins p47-phox and p67-phox. *J. Exp. Med.* 180, 2329-2334
- 133. Leusen JH**, de Klein A, Hilarius PM, Ahlin A, Palmblad J, Smith CI, Diekmann D, Hall A, Verhoeven AJ, Roos D. (1996) Disturbed interaction of p21-rac with mutated p67-phox causes chronic granulomatous disease. *J. Exp. Med.* 184, 1243-1249
- 134. Leusen JH**, Meischl C, Eppink MH, Hilarius PM, de Boer M, Weening RS, Ahlin A, Sanders L, Goldblatt D, Skopczynska H, Bernatowska E, Palmblad J, Verhoeven AJ, van Berkel WJ, Roos D. (2000) Four novel mutations in the gene encoding gp91-phox of human NADPH oxidase: consequences for oxidase assembly. *Blood* 95, 666-673
- 135. Li F**, Linton GF, Sekhsaria S, Whiting-Theobald N, Katkin JP, Gallin JI, Malech HL. (1994) CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease. *Blood* 84, 53-58
- 136. Li XJ**, Grunwald D, Mathieu J, Morel F, Stasia MJ. (2005) Crucial role of two potential cytosolic regions of Nox2, 191TSSTKTIRRS200 and 484DESQLANHFVHHDEEKD500, on NADPH oxidase activation. *J. Biol. Chem.* 280, 14962-14973
- 137. Light DR**, Walsh C, O'Callaghan AM, Goetzl EJ, Tauber AI. (1981) Characteristics of the cofactor requirements for the superoxide-generating NADPH oxidase of human polymorphonuclear leukocytes. *Biochemistry* 20, 1468-1476

- 138. Lomax KJ**, Leto TL, Nunoi H, Gallin JI, Malech HL. (1989) Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. *Science* 245, 409-412
- 139. Malech HL**, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Butz RE, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Gallin JI. (1997) Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. *Proc. Natl. Acad. Sci. U S A.* 94, 12133-12138
- 140. Maly FE**, Cross AR, Jones OT, Wolf-Vorbeck G, Walker C, Dahinden CA, De Weck AL. (1988) The superoxide generating system of B cell lines. Structural homology with the phagocytic oxidase and triggering via surface Ig. *J. Immunol.* 140, 2334-2339
- 141. Maly FE**, Schuerer-Maly CC, Quilliam L, Cochrane CG, Newburger PE, Curnutte JT, Gifford M, Dinauer MC. (1993) Restitution of superoxide generation in autosomal cytochrome-negative chronic granulomatous disease (A22(0) CGD)-derived B lymphocyte cell lines by transfection with p22phox cDNA. *J. Exp. Med.* 178, 2047-2053
- 142. Maly FE**, Quilliam LA, Dorseuil O, Der CJ, Bokoch GM. (1994) Activated or dominant inhibitory mutants of Rap1A decrease the oxidative burst of Epstein-Barr virus-transformed human B lymphocytes. *J. Biol. Chem.* 269, 18743-18746
- 143. Mankelov TJ**, Pessach E, Levy R, Henderson LM. (2003a) The requirement of cytosolic phospholipase A2 for the PMA activation of proton efflux through the N-terminal 230-amino-acid fragment of gp91phox. *Biochem. J.* 374, 315-319
- 144. Mankelov TJ**, Henderson LM. (2003b) Proton conduction through full-length gp91phox requires histidine 115. *Protoplasma* 221, 101-108
- 145. Mankelov TJ**, Hu XW, Adams K, Henderson LM. (2004) Investigation of the contribution of histidine 119 to the conduction of protons through human Nox2. *Eur. J. Biochem.* 271, 4026-4033
- 146. Massenot C**, Chenavas S, Cohen-Addad C, Dagher MC, Brandolin G, Pebay-Peyroula E, Fieschi F. (2005) Effects of p47phox C terminus phosphorylations on binding interactions with p40phox and p67phox. Structural and functional comparison of p40phox and p67phox SH3 domains. *J. Biol. Chem.* 280, 13752-13761
- 147. Maturana A**, Arnaudeau S, Ryser S, Banfi B, Hossle JP, Schlegel W, Krause KH, Demaurex N. (2001) Heme histidine ligands within gp91(phox) modulate proton conduction by the phagocyte NADPH oxidase. *J. Biol. Chem.* 276, 30277-30284
- 148. Maturana A**, Krause KH, Demaurex N. (2002) NOX family NADPH oxidases: do they have built-in proton channels? *J. Gen. Physiol.* 120, 781-786
- 149. Morel F**, Doussiere J, Stasia MJ, Vignais PV. (1985) The respiratory burst of bovine neutrophils. Role of a b type cytochrome and coenzyme specificity. *Eur. J. Biochem.* 152, 669-679
- 150. Morgan D**, Cherny VV, Price MO, Dinauer MC, DeCoursey TE. (2002) Absence of proton channels in COS-7 cells expressing functional NADPH oxidase components. *J. Gen. Physiol.* 119, 571-580
- 151. Murillo I**, Henderson LM. (2005) Expression of gp91phox/Nox2 in COS-7 cells: cellular localization of the protein and the detection of outward proton currents. *Biochem. J.* 385, 649-657
- 152. Nakanishi A**, Imajoh-Ohmi S, Fujinawa T, Kikuchi H, Kanegasaki S. (1992) Direct evidence for interaction between COOH-terminal regions of cytochrome b558 subunits and cytosolic 47-kDa protein during activation of an O(2-)-generating system in neutrophils. *J. Biol. Chem.* 267, 19072-19074
- 153. Nanda A**, Romanek R, Curnutte JT, Grinstein S. (1994) Assessment of the contribution of the cytochrome b moiety of the NADPH oxidase to the transmembrane H⁺ conductance of leukocytes. *J. Biol. Chem.* 269, 27280-27285

- 154.Nebl T**, Pestonjamasp KN, Leszyk JD, Crowley JL, Oh SW, Luna EJ. (2002) Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes. *J. Biol. Chem.* 277, 43399-43409
- 155.Nisimoto Y**, Motalebi S, Han CH, Lambeth JD. (1999) The p67(phox) activation domain regulates electron flow from NADPH to flavin in flavocytochrome b(558). *J. Biol. Chem.* 274, 22999-23005
- 156.Nisimoto Y**, Ogawa H, Miyano K, Tamura M. (2004) Activation of the flavoprotein domain of gp91phox upon interaction with N-terminal p67phox (1-210) and the Rac complex. *Biochemistry* 43, 9567-9575
- 157.Nunoi H**, Rotrosen D, Gallin JI, Malech HL. (1988) Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. *Science* 242, 1298-1301
- 158.Orkin SH**. (1989) Molecular genetics of chronic granulomatous disease. *Annu. Rev. Immunol.* 7, 277-307
- 159.Ott GM**, Stein S, Koehl U, Kunkel H, Siler U, Schilz A, Kuhlcke K, Schmidt M, Von Kalle C, Hassan M, Hoelzer D, Seger R, Grez M. (2004) XIth Meeting for the European Society for Immunodeficiencies (ESID) 21-24 October
- 160.Paclet MH**, Coleman AW, Vergnaud S, Morel F. (2000) P67-phox-mediated NADPH oxidase assembly: imaging of cytochrome b558 liposomes by atomic force microscopy. *Biochemistry* 39, 9302-9310
- 161.Paclet MH**, Henderson LM, Campion Y, Morel F, Dagher MC. (2004) Localization of Nox2 N-terminus using polyclonal antipeptide antibodies. *Biochem. J.* 382, 981-986
- 162.Paffenholz R**, Bergstrom RA, Pasutto F, Wabnitz P, Munroe RJ, Jagla W, Heinzmann U, Marquardt A, Bareiss A, Laufs J, Russ A, Stumm G, Schimenti JC, Bergstrom DE. (2004) Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase. *Genes Dev.* 18, 486-491
- 163.Park MY**, Imajoh-Ohmi S, Nunoi H, Kanegasaki S. (1994) Peptides corresponding to the region adjacent to His-94 in the small subunit of cytochrome b558 inhibit superoxide generation in a cell-free system from human neutrophils. *Biochem. Biophys. Res. Commun.* 204, 924-929
- 164.Park MY**, Imajoh-Ohmi S, Nunoi H, Kanegasaki S. (1997) Synthetic peptides corresponding to various hydrophilic regions of the large subunit of cytochrome b558 inhibit superoxide generation in a cell-free system from neutrophils. *Biochem. Biophys. Res. Commun.* 234, 531-536
- 165.Parkos CA**, Allen RA, Cochrane CG, Jesaitis AJ. (1987) Purified cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000. *J Clin Invest.* 80, 732-742
- 166.Pedruzzi E**, Fay M, Elbim C, Gaudry M, Gougerot-Pocidal MA. (2002) Differentiation of PLB-985 myeloid cells into mature neutrophils, shown by degranulation of terminally differentiated compartments in response to N-formyl peptide and priming of superoxide anion production by granulocyte-macrophage colony-stimulating factor. *Br. J. Haematol.* 117, 719-726
- 167.Pessach I**, Leto TL, Malech HL, Levy R. (2001) Essential requirement of cytosolic phospholipase A(2) for stimulation of NADPH oxidase-associated diaphorase activity in granulocyte-like cells. *J. Biol. Chem.* 276, 33495-33503
- 168.Pick E**, Gorzalczany Y, Engel S. (1993) Role of the rac1 p21-GDP-dissociation inhibitor for rho heterodimer in the activation of the superoxide-forming NADPH oxidase of macrophages. *Eur. J. Biochem.* 217, 441-455
- 169.Porter CD**, Parkar MH, Levinsky RJ, Collins MK, Kinnon C. (1993) X-linked chronic granulomatous disease: correction of NADPH oxidase defect by retrovirus-mediated expression of gp91-phox. *Blood* 82, 2196-2202
- 170.Porter CD**, Parkar MH, Verhoeven AJ, Levinsky RJ, Collins MK, Kinnon C. (1994) p22-phox-deficient chronic granulomatous disease: reconstitution by retrovirus-mediated expression and identification of a biosynthetic intermediate of gp91-phox. *Blood* 84, 2767-2775

171. **Price MO**, McPhail LC, Lambeth JD, Han CH, Knaus UG, Dinauer MC. (2002) Creation of a genetic system for analysis of the phagocyte respiratory burst: high-level reconstitution of the NADPH oxidase in a nonhematopoietic system. *Blood* 99, 2653-2661
172. **Quilliam LA**, Mueller H, Bohl BP, Prossnitz V, Sklar LA, Der CJ, Bokoch GM. (1991) Rap1A is a substrate for cyclic AMP-dependent protein kinase in human neutrophils. *J. Immunol.* 147, 1628–1635
173. **Quinn MT**, Parkos CA, Walker L, Orkin SH, Dinauer MC and Jesaitis AJ. (1989) Association of a Ras-related protein with cytochrome b of human neutrophils. *Nature* 342, 198–200
174. **Quinn MT**, Mullen ML, Jesaitis AJ. (1992a) Human neutrophil cytochrome b contains multiple hemes. Evidence for heme associated with both subunits. *J. Biol. Chem.* 267, 7303-7309
175. **Quinn MT**, Mullen ML, Jesaitis AJ, Linner JG. (1992b) Subcellular distribution of the Rap1A protein in human neutrophils: colocalization and cotranslocation with cytochrome b559. *Blood* 79, 1563–1573
176. **Quinn MT**, Curnutte JT, Parkos CA, Mullen ML, Scott PJ, Erickson RW, Jesaitis AJ. (1992c) Reconstitution of defective respiratory burst activity with partially purified human neutrophil cytochrome B in two genetic forms of chronic granulomatous disease: possible role of Rap1A. *Blood* 79, 2438-2445
177. **Quinn MT**, Parkos CA, Jesaitis AJ. (1995) Purification of human neutrophil NADPH oxidase cytochrome b-558 and association with Rap 1A. *Methods Enzymol.* 255, 476-487
178. **Quinn MT**, Gauss KA. (2004) Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. *J. Leukoc. Biol.* 76, 760-781
179. **Rada BK**, Geiszt M, Kaldi K, Timar C, Ligeti E. (2004) Dual role of phagocytic NADPH oxidase in bacterial killing. *Blood* 104, 2947-2953
180. **Rae J**, Newburger PE, Dinauer MC, Noack D, Hopkins PJ, Kuruto R, Curnutte JT. (1998) X-Linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. *Am J Hum. Genet.* 62, 1320-1331
181. **Ravel P**, Lederer F. (1991) Inactivation of NADPH oxidase from human neutrophils by affinity labeling with pyridoxal 5'-diphospho-5'-adenosine. *Biochem. Biophys. Res. Commun.* 181, 1259-1265
182. **Ravel P**, Lederer F. (1993) Affinity-labeling of an NADPH-binding site on the heavy subunit of flavocytochrome b558 in particulate NADPH oxidase from activated human neutrophils. *Biochem. Biophys. Res. Commun.* 196, 543-552
183. **Reeves EP**, Lu H, Jacobs HL, Messina CG, Bolsover S, Gabella G, Potma EO, Warley A, Roes J, Segal AW. (2002) Killing activity of neutrophils is mediated through activation of proteases by K⁺ flux. *Nature* 416, 291-297
184. **Rinckel LA**, Faris SL, Hitt ND, Kleinberg ME. (1999) Rac1 disrupts p67phox/p40phox binding: a novel role for Rac in NADPH oxidase activation. *Biochem. Biophys. Res. Commun.* 263, 118-122
185. **Roesler J**, Heyden S, Burdelski M, Schafer H, Kreth HW, Lehmann R, Paul D, Marzahn J, Gahr M, Rosen-Wolff A. (1999) Uncommon missense and splice mutations and resulting biochemical phenotypes in German patients with X-linked chronic granulomatous disease. *Exp. Hematol.* 27, 505-511
186. **Roesler J**, Curnutte JT, Rae J, Barrett D, Patino P, Chanock SJ, Goerlach A. (2000) Recombination events between the p47-phox gene and its highly homologous pseudogenes are the main cause of autosomal recessive chronic granulomatous disease. *Blood* 95, 2150-2156
187. **Roos D**. (1994) The genetic basis of chronic granulomatous disease. *Immunol. Rev.* 138, 121-157
188. **Roos D**, de Boer M, Kuribayashi F, Meischl C, Weening RS, Segal AW, Ahlin A, Nemet K, Hossle JP, Bernatowska-Matuszkiewicz E, Middleton-Price H. (1996a) Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. *Blood* 87, 1663-1681
189. **Roos D**. (1996b) X-CGDbase: a database of X-CGD-causing mutations. *Immunol. Today* 17, 517-521

- 190. Roos D**, van Bruggen R, Meischl C. (2003) Oxidative killing of microbes by neutrophils. *Microbes Infect.* 5, 1307-1315
- 191. Rossi F**, Zatti M. (1964) Changes in the metabolic pattern of polymorpho-nuclear leucocytes during phagocytosis. *Br. J. Exp. Pathol.* 45, 548-559
- 192. Rotrosen D**, Kleinberg ME, Nunoi H, Leto T, Gallin JI, Malech HL. (1990) Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. *J. Biol. Chem.* 265, 8745-8750
- 193. Rotrosen D**, Yeung CL, Leto TL, Malech HL, Kwong CH. (1992) Cytochrome b558: the flavin-binding component of the phagocyte NADPH oxidase. *Science* 256, 1459-1462
- 194. Royer-Pokora B**, Kunkel LM, Monaco AP, Goff SC, Newburger PE, Baehner RL, Cole FS, Curnutte JT, Orkin SH. (1986) Cloning the gene for an inherited human disorder--chronic granulomatous disease--on the basis of its chromosomal location. *Nature* 322, 32-38
- 195. Sathymoorthy M**, de Mendez I, Adams AG, Leto TL. (1997) p40(phox) down-regulates NADPH oxidase activity through interactions with its SH3 domain. *J. Biol. Chem.* 272, 9141-9146
- 196. Sbarra AJ**, Karnovsky ML. (1959) The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. *J. Biol. Chem.* 234, 1355-1362
- 197. Schapiro BL**, Newburger PE, Klempner MS, Dinauer MC. (1991) Chronic granulomatous disease presenting in a 69-year-old man. *N. Engl. J. Med.* 325, 1786-1790
- 198. Schrenzel J**, Serrander L, Banfi B, Nusse O, Fouyouzi R, Lew DP, Demaurex N, Krause KH. (1998) Electron currents generated by the human phagocyte NADPH oxidase. *Nature* 392, 734-737
- 199. Segal AW**, Jones OT. (1978) Novel cytochrome b system in phagocytic vacuoles of human granulocytes. *Nature* 276, 515-517
- 200. Segal AW**, Garcia R, Goldstone H, Cross AR, Jones OT. (1981) Cytochrome b-245 of neutrophils is also present in human monocytes, macrophages and eosinophils. *Biochem. J.* 196, 363-367
- 201. Segal AW**, Heyworth PG, Cockcroft S, Barrowman MM. (1985) Stimulated neutrophils from patients with autosomal recessive chronic granulomatous disease fail to phosphorylate a Mr-44,000 protein. *Nature* 316, 547-549
- 202. Segal AW**, West I, Wientjes F, Nugent JH, Chavan AJ, Haley B, Garcia RC, Rosen H, Scrace G. (1992) Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes. *Biochem. J.* 284, 781-788
- 203. Segal AW**. (1996) The NADPH oxidase and chronic granulomatous disease. *Mol. Med. Today* 2, 129-135
- 204. Segal BH**, Leto TL, Gallin JI, Malech HL, Holland SM. (2000) Genetic, biochemical, and clinical features of chronic granulomatous disease. *Medicine* 79, 170-300
- 205. Selvaraj RJ**, Sbarra AJ. (1966) Relationship of glycolytic and oxidative metabolism to particle entry and destruction in phagocytosing cells. *Nature* 211, 1272-1276
- 206. Shao D**, Segal AW, Dekker LV. (2003) Lipid rafts determine efficiency of NADPH oxidase activation in neutrophils. *FEBS Lett.* 550, 101-106
- 207. Shatwell KP**, Dancis A, Cross AR, Klausner RD, Segal AW. (1996) The FRE1 ferric reductase of *Saccharomyces cerevisiae* is a cytochrome b similar to that of NADPH oxidase. *J. Biol. Chem.* 271, 14240-14244
- 208. Smith RM**, Connor JA, Chen LM, Babior BM. (1996) The cytosolic subunit p67phox contains an NADPH binding site that participates in catalysis by the leukocyte NADPH oxidase. *J. Clin. Invest.* 98, 977-983
- 209. Someya A**, Nagaoka I, Yamashita T. (1993) Purification of the 260 kDa cytosolic complex involved in the superoxide production of guinea pig neutrophils. *FEBS Lett.* 330, 215-218

- 210. Stahelin RV**, Burian A, Bruzik KS, Murray D, Cho W. (2003) Membrane binding mechanisms of the PX domains of NADPH oxidase p40phox and p47phox. *J. Biol. Chem.* 278, 14469-14479
- 211. Stasia MJ**, Lardy B, Maturana A, Rousseau P, Martel C, Bordigoni P, Demareux N, Morel F. (2002a) Molecular and functional characterization of a new X-linked chronic granulomatous disease variant (X91+) case with a double missense mutation in the cytosolic gp91phox C-terminal tail. *Biochim. Biophys. Acta.* 1586, 316-330
- 212. Stasia MJ**, Bordigoni P, Martel C, Morel F. (2002b) A novel and unusual case of chronic granulomatous disease in a child with a homozygous 36-bp deletion in the CYBA gene (A22(0)) leading to the activation of a cryptic splice site in intron 4. *Hum. Genet.* 110, 444-450
- 213. Stasia MJ**, Brion JP, Boutonnat J, Morel F. (2003) Severe clinical forms of cytochrome b-negative chronic granulomatous disease (X91-) in 3 brothers with a point mutation in the promoter region of CYBB. *J. Infect Dis.* 188, 1593-1604
- 214. Stasia MJ**, Bordigoni P, Floret D, Brion JP, Bost-Bru C, Michel G, Gatel P, Durant-Vital D, Voelckel MA, Li XJ, Guillot M, Maquet E, Martel C, Morel F. (2005) Characterization of six novel mutations in the CYBB gene leading to different sub-types of X-linked chronic granulomatous disease. *Hum. Genet.* 116, 72-82
- 215. Sugimoto Y**, Tsukahara S, Sato S, Suzuki M, Nunoi H, Malech HL, Gottesman MM, Tsuruo T. (2003) Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91. *J. Gene Med.* 5, 366-376
- 216. Suh YA**, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD. (1999) Cell transformation by the superoxide-generating oxidase Mox1. *Nature* 401, 79-82
- 217. Sumimoto H**, Sakamoto N, Nozaki M, Sakaki Y, Takeshige K, Minakami S. (1992) Cytochrome b558, a component of the phagocyte NADPH oxidase, is a flavoprotein. *Biochem. Biophys. Res. Commun.* 186, 1368-1375
- 218. Sumimoto H**, Kage Y, Nunoi H, Sasaki H, Nose T, Fukumaki Y, Ohno M, Minakami S, Takeshige K. (1994) Role of Src homology 3 domains in assembly and activation of the phagocyte NADPH oxidase. *Proc. Natl. Acad. Sci. U S A.* 91, 5345-5349
- 219. Sumimoto H**, Hata K, Mizuki K, Ito T, Kage Y, Sakaki Y, Fukumaki Y, Nakamura M, Takeshige K. (1996) Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N-terminal Src homology 3 domain of p47phox with p22phox is required for activation of the NADPH oxidase. *J. Biol. Chem.* 271, 22152-22158
- 220. Takeya R**, Ueno N, Kami K, Taura M, Kohjima M, Izaki T, Nunoi H, Sumimoto H. (2003) Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. *J. Biol. Chem.* 278, 25234-25246
- 221. Tanugi-Cholley LC**, Issartel JP, Lunardi J, Freycon F, Morel F, Vignais PV. (1995) A mutation located at the 5' splice junction sequence of intron 3 in the p67phox gene causes the lack of p67phox mRNA in a patient with chronic granulomatous disease. *Blood* 85, 242-249
- 222. Taylor WR**, Jones DT, Segal AW. (1993) A structural model for the nucleotide binding domains of the flavocytochrome b-245 beta-chain. *Protein Sci.* 2, 1675-1685
- 223. Teahan C**, Rowe P, Parker P, Totty N, Segal AW. (1987) The X-linked chronic granulomatous disease gene codes for the beta-chain of cytochrome b-245. *Nature* 327, 720-721
- 224. Thrasher A**, Chetty M, Casimir C, Segal AW. (1992) Restoration of superoxide generation to a chronic granulomatous disease-derived B-cell line by retrovirus mediated gene transfer. *Blood* 80, 1125-1129
- 225. Thrasher AJ**, Keep NH, Wientjes F, Segal AW. (1994) Chronic granulomatous disease. *Biochim Biophys. Acta.* 1227, 1-24

226. **Touret N**, Grinstein S. (2002) Voltage-gated proton "channels": a spectator's viewpoint. *J. Gen. Physiol.* 120, 767-771
227. **Tsuchiya T**, Imajoh-Ohmi S, Nunoi H, Kanegasaki S. (1999) Uncompetitive inhibition of superoxide generation by a synthetic peptide corresponding to a predicted NADPH binding site in gp91-phox, a component of the phagocyte respiratory oxidase. *Biochem. Biophys. Res. Commun.* 257, 124-128
228. **Tsuda M**, Kaneda M, Sakiyama T, Inana I, Owada M, Kiryu C, Shiraishi T, Kakinuma K. (1998) A novel mutation at a probable heme-binding ligand in neutrophil cytochrome b558 in atypical X-linked chronic granulomatous disease. *Hum. Genet.* 103, 377-381
229. **Tsunawaki S**, Kagara S, Yoshikawa K, Yoshida LS, Kuratsuji T, Namiki H. (1996) Involvement of p40phox in activation of phagocyte NADPH oxidase through association of its carboxyl-terminal, but not its amino-terminal, with p67phox. *J. Exp. Med.* 184, 893-902
230. **Tucker KA**, Lilly MB, Heck L Jr, Rado TA. (1987) Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. *Blood* 70, 372-378
231. **Ueno N**, Takeya R, Miyano K, Kikuchi H, Sumimoto H. (2005) The NADPH oxidase Nox3 constitutively produces superoxide in a p22phox-dependent manner: Its regulation by oxidase organizers and activators. *J. Biol. Chem.* 280, 23328-23339
232. **Uhlinger DJ**, Tyagi SR, Lambeth JD. (1995) On the mechanism of inhibition of the neutrophil respiratory burst oxidase by a peptide from the C-terminus of the large subunit of cytochrome b558. *Biochemistry* 34, 524-527
233. **Vazquez N**, Lehrnbecher T, Chen R, Christensen BL, Gallin JI, Malech H, Holland S, Zhu S, Chanock SJ. (2001) Mutational analysis of patients with p47-phox-deficient chronic granulomatous disease: The significance of recombination events between the p47-phox gene (NCF1) and its highly homologous pseudogenes. *Exp. Hematol.* 29, 234-243
234. **Vergnaud S**, Pacllet MH, El Benna J, Pocard MA, Morel F. (2000) Complementation of NADPH oxidase in p67-phox-deficient CGD patients p67-phox/p40-phox interaction. *Eur. J. Biochem.* 267, 1059-1067
235. **Vignais PV**. (2002) The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. *Cell Mol. Life Sci.* 59, 1428-1459
236. **Vilhardt F, van Deurs B**. (2004) The phagocyte NADPH oxidase depends on cholesterol-enriched membrane microdomains for assembly. *EMBO J.* 23, 739-748
237. **Volkman DJ**, Buescher ES, Gallin JI, Fauci AS. (1984) B cell lines as models for inherited phagocytic diseases: abnormal superoxide generation in chronic granulomatous disease and giant granules in Chediak-Higashi syndrome. *J. Immunol.* 133, 3006-3009
238. **Volpp BD**, Nauseef WM, Clark RA. (1988) Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. *Science* 242, 1295-1297
239. **Volpp BD**, Nauseef WM, Donelson JE, Moser DR, Clark RA. (1989) Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. *Proc. Natl. Acad. Sci. U S A.* 86, 7195-7199
240. **Wallach TM**, Segal AW. (1996) Stoichiometry of the subunits of flavocytochrome b558 of the NADPH oxidase of phagocytes. *Biochem. J.* 320, 33-38
241. **Wallach TM**, Segal AW. (1997) Analysis of glycosylation sites on gp91phox, the flavocytochrome of the NADPH oxidase, by site-directed mutagenesis and translation in vitro. (1997) *Biochem. J.* 321, 583-585
242. **Weening RS**, Kabel P, Pijman P, Roos D. (1983) Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease. *J. Pediatr.* 103, 127-130

- 243. Winkelstein JA**, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H. (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. *Medicine (Baltimore)* 79, 155-169
- 244. Woodman RC**, Newburger PE, Anklesaria P, Erickson RW, Rae J, Cohen MS, Curnutte JT. (1995) A new X-linked variant of chronic granulomatous disease characterized by the existence of a normal clone of respiratory burst-competent phagocytic cells. *Blood* 85, 231-241
- 245. Yamauchi A**, Yu L, Potgens AJ, Kuribayashi F, Nunoi H, Kanegasaki S, Roos D, Malech HL, Dinauer MC, Nakamura M. (2001) Location of the epitope for 7D5, a monoclonal antibody raised against human flavocytochrome b558, to the extracellular peptide portion of primate gp91phox. *Microbiol. Immunol.* 45, 249-257
- 246. Yoshida LS**, Saruta F, Yoshikawa K, Tatsuzawa O, Tsunawaki S. (1998) Mutation at histidine 338 of gp91(phox) depletes FAD and affects expression of cytochrome b558 of the human NADPH oxidase. *J. Biol. Chem.* 273, 27879-27886
- 247. Yu L**, Zhen L, Dinauer MC. (1997) Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. *J. Biol. Chem.* 272, 27288-2729
- 248. Yu L**, Quinn MT, Cross AR, Dinauer MC. (1998) Gp91(phox) is the heme binding subunit of the superoxide-generating NADPH oxidase. *Proc. Natl. Acad. Sci. U S A.* 95, 7993-7998
- 249. Yu L**, DeLeo FR, Biberstine-Kinkade KJ, Renee J, Nauseef WM, Dinauer MC. (1999a) Biosynthesis of flavocytochrome b558. gp91(phox) is synthesized as a 65-kDa precursor (p65) in the endoplasmic reticulum. *J. Biol. Chem.* 274, 4364-4369
- 250. Yu L**, Cross AR, Zhen L, Dinauer MC. (1999b) Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488-497 gp91(phox) deletion mutant. *Blood* 94, 2497-2504
- 251. Zhan Y**, Virbasius JV, Song X, Pomerleau DP, Zhou GW. (2002) The p40phox and p47phox PX domains of NADPH oxidase target cell membranes via direct and indirect recruitment by phosphoinositides. *J. Biol. Chem.* 277, 4512-4518
- 252. Zhan Y**, He D, Newburger PE, Zhou GW. (2004) p47(phox) PX domain of NADPH oxidase targets cell membrane via moesin-mediated association with the actin cytoskeleton. *J. Cell Biochem.* 92, 795-809
- 253. Zhen L**, King AA, Xiao Y, Chanock SJ, Orkin SH, Dinauer MC. (1993) Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. *Proc. Natl. Acad. Sci. U S A.* 90, 9832-9836
- 254. Zhen L**, Yu L, Dinauer MC. (1998) Probing the role of the carboxyl terminus of the gp91phox subunit of neutrophil flavocytochrome b558 using site-directed mutagenesis. *J. Biol. Chem.* 273, 6575-6581